Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05046613 · ClinicalTrials.gov registry record
Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant
A clinical trial of Migraine, sponsored by Pfizer.
- Recruiting
- Registry status
- 780
- Enrollment target
- 1
- Study location
NCT05046613: Recruiting study of Migraine, sponsored by Pfizer.
NCT05046613 is a study of Migraine that is actively recruiting participants, run by Pfizer. The registered enrollment target is 780 participants, above the 351-participant average among 102 other Migraine trials with a reported enrollment target (122% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05046613, a study of Migraine, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- 780 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate fetal, maternal, and infant outcomes through 12 months of age.
Primary Outcome
Healthcare provider report through the registry
Conditions Studied
Interventions
- OTHER Rimegepant
- OTHER Not taking Rimegepant
Study Locations (1)
North Carolina
- Evidera, a PPD business unit - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 780 participants |
| Start Date | 2021-09-23 |
| Est. Completion | 2034-04-30 |
What NCT05046613 shows while recruiting
NCT05046613 is an observational study that tracks outcomes without assigning an intervention. The registered 780 participants enrollment target is mid-sized for trials with a published cap, above the 351-participant average among 102 other Migraine trials with a reported enrollment target (122% higher).
The record links to 1 condition, with Migraine appearing as the primary indexed condition, and to 2 interventions - of which Rimegepant is the first listed.
NCT05046613 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT05046613 about?
NCT05046613 is a clinical study titled "Observational Study to Assess Maternal, Fetal and Infant Outcomes Following Exposure to Rimegepant". The purpose of the study is to evaluate fetal, maternal, and infant outcomes through 12 months of age.
What is the current status of trial NCT05046613?
This trial is currently recruiting. The enrollment target is 780 participants. The study started on 2021-09-23. Estimated completion is 2034-04-30.
What conditions does trial NCT05046613 study?
This clinical trial studies the following conditions: Migraine.
What interventions are being tested in trial NCT05046613?
The interventions under investigation include: Rimegepant (OTHER), Not taking Rimegepant (OTHER).
Who is sponsoring clinical trial NCT05046613?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05046613 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05046613's enrollment target sits among peer trials
780 13th of 102 higher than 90 of 102 other Migraine trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Migraine trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Migraine Manager (R01)
RECRUITING · Phase 2
-
MMA Embolization for Refractory Chronic Migraine
RECRUITING · NA
-
Stimulation of External Carotid Artery Circulation
RECRUITING · NA
-
Efficacy of Xeomin for Migraines in Patients With Traumatic Brain Injuries vs. Anomalous Health Incidents
RECRUITING
-
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine
RECRUITING · Phase 3
-
Mechanistic Studies of Psilocybin in Headache Disorders
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05100862 · 780 participants · Phase 3
A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma
- NCT05513872 · 780 participants · Phase 1
Overcoming Nicotine Dependence to Enable Quitting
- NCT06310031 · 780 participants · NA
Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure
- NCT06312137 · 780 participants · Phase 3
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI